SGO Meeting Highlights via Twitter ~ Day 4, March 15

Updated with additional tweets 7:32 pm 3/15/17.

Today was the last day of The Society of Gynecologic Oncology (@SGO_org) Annual Meeting (#SGOmtg). Believe it or not as I type this the snow is falling again.

Here are some tweets I found interesting today.

Patient Preferences:
WRITE Symptoms Study (GOG 259):

TY Dr. Donovan for very imp work symptom mgmt & intervention for women living with recurrent #ovariancancer. Understudied! #SGOmtg #gyncsm pic.twitter.com/F0BWU6wts0

— Annie Ellis (@Stigetta) March 15, 2017

@womenofteal top 10 for symptom mgmt: fatigue sleep-disturbance pain anxiety neuropathy constpation memory nausea bloating drowsiness pic.twitter.com/92ySkxfMlZ

— Annie Ellis (@Stigetta) March 15, 2017

@womenofteal pic.twitter.com/3nvk7knJH8

— Annie Ellis (@Stigetta) March 15, 2017

@womenofteal pic.twitter.com/X4QFb3RSpn

— Annie Ellis (@Stigetta) March 15, 2017

Cohn: Understanding patient pref re toxicities critical 2 enhancing shared decision making. YES!!! #SGOMtg Need tools along tx continuum pic.twitter.com/g4kFW1QSLW

— Annie Ellis (@Stigetta) March 15, 2017

Palliative Care:

Nevadunsky: Early palliative care assoc w/improved quality of end of life care #SGOMtg #gyncsm Diverse study population! Very important! pic.twitter.com/8Zss67Ywpr

— Annie Ellis (@Stigetta) March 15, 2017

"Early palliative care is feasible & increases access 4 ethnically/racially diverse women w/ Gyn cancers." Dr. Nevadunsky @SGO2017 #SGOMtg

— Carol Brown (@drcarolbrownMSK) March 15, 2017

Ovarian Cancer:

Myriad data presented at #SGOMtg confirms older mean age at diagnosis of #ovariancancer in BRIP1 and RAD51C germline mutation carriers.

— Douglas Levine MD (@levinemd) March 15, 2017

Chemotherapy Induces Molecular Changes in High-Grade Serous Ovarian Carcinoma #SGOMtg https://t.co/jzLlJXBQtB

— Linus T Chuang (@linuscmd) March 15, 2017

Cervical Cancer

2017 #SGOMtg coverage: High rates of persistent opioid use 6 months after RT for cervical cancerhttps://t.co/DIRlIn5fdl pic.twitter.com/UMWPurj87c

— SGO (@SGO_org) March 15, 2017

A big shout out to all the researchers, gyn oncs, advocates  and others who tweeted from the meeting.Thanks! 

I look forward to April's  #gyncsm chat (April 12, 2017 at 9pm) recapping this year's meeting.

Dee
Every Day is a Blessing!

SGO Meeting Highlights via Twitter ~ Day Three, March 14, 2017

I am at home watching the snow fall and following Tweets from The Society of Gynecologic Oncology (@SGO_org) Annual Meeting using the hashtag #SGOmtg.

Here are some tweets fromTuesday, March 14,2017 ( Pi day!)

Other sources of Meeting coverage:

Stay up to date on the #SGOMtg with our conference coverage! https://t.co/dzpWAtqAlW

— CURE Magazine (@cure_magazine) March 14, 2017

Endometrial Cancer

MMR Deficiency Linked to PD-L1 Expression in Endometrial Cancer https://t.co/E0LI2OzxDO #SGOmtg

— OncLive.com (@OncLive) March 14, 2017

Sentinel lymph mode mapping is #costeffective for the treatment of #endometrial cancer! #SGOMtg #gyncsm #endcancer great job @SuidanRudy https://t.co/uZxo7RB7NV

— Shannon Westin (@ShannonWestin) March 14, 2017

Ovarian cancer
GOG-3003 Compares pegylated liposomal doxorubicin (PLD) to PLD in combination with motolimod (a new type of investigational drug that stimulates the immune system)

Motolimod is an agonist for TLR8 in GOG-3003. Combo with PLD in #ovariancancer had no improvement in OS or PFS. #SGOMtg

— Rebecca Previs (@BeccaPrevisMD) March 14, 2017

     SOLO2 Trial studied LYNPARZA as maintenance treatment for women with BRCA-mutated metastatic ovarian cancer

SOLO2 primary endpoint was PFS, not OS (key secondary endpt) #SGOMtg

— Don S Dizon (@drdonsdizon) March 14, 2017

SOLO2 data presented at #SGOMtg: PFS advantage in olaparib maintenance arm for BRCAmut recurrent ovary cancer. Compelling. #parpi

— Jenny Mueller MD (@JennyMueller_) March 14, 2017

SOLO2:  Time to First Secondary Treatment- 27.9 months vs 7.1 (HR 0.28; p <0.0001) in favor of olaparib -  WOW!!!! #SGOMtg

— Tabari (@Tabari_B) March 14, 2017

37% using olaparib had a grade 3 or higher adverse event (vs 18% with placebo) #SOLO2 #SGOMtg

— Don S Dizon (@drdonsdizon) March 14, 2017

GOG-212

Late breaking abstract time. First up GOG212. #SGOmtg pic.twitter.com/qcprT7KBBp

— Annie Ellis (@Stigetta) March 14, 2017

#SGOMtg #GOG212: example that more treatment is not always better.No improvement in OS despite slight PFS improvement.

— Deanna Teoh, M.D. (@DeannaTeoh) March 14, 2017

GOG212: Surveillance v Taxol x12 vs CT2103 x12. Primary endpoint OS. #SGOMtg Activated 12 years ago!

— Don S Dizon (@drdonsdizon) March 14, 2017

Both Taxol and CT-2103 showed clinically meaningful and worse neurotoxicity vs surveillance in GOG212 @copebuckeye #SGOMtg

— Don S Dizon (@drdonsdizon) March 14, 2017

Stress

Fascinating research approach integrating basic science and big database looking at drug combo and stress in ov ca from @DrRobDood #SGOMtg pic.twitter.com/fsn0nB0ptE

— Katie Kurnit (@katiekurnit) March 14, 2017

Uterine Carcinosarcoma

TP53 mutations are most common in our study of carcinosarcoma #uterinecancer @nicoleflemingmd #endcancer #SGOMtg pic.twitter.com/maPL5RROhA

— Rebecca Previs (@BeccaPrevisMD) March 14, 2017

Cervical Cancer
AXAL :Phase 2 study axalimogene filolisbac (AXAL), in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix 

Improved OS over historical controls with AXAL in recurrent #cervical cancer! Big news.  #SGOMtg #gyncsm https://t.co/whlS6QOBBi

— Shannon Westin (@ShannonWestin) March 14, 2017

AXAL: live attenuated listeria based immnotherapy that secretes HPV-16 E7 protein fused with a truncated fragment of listeriolysin O #SGOMtg

— Don S Dizon (@drdonsdizon) March 14, 2017

General

#quality research improves outcomes!  Reduced blood transfusions = less cost and better outcomes. Great job @LPrescottMD #SGOMtg #gyncsm https://t.co/FJpqGHRDXe

— Shannon Westin (@ShannonWestin) March 14, 2017

Sunrise Session. Dr. Annunziata says Phase 2/3 trials and inclusion of biomarker targeting/analysis are the future #SGOMtg

— A.C. Evans, MD, PhD (@gynoncdoc) March 14, 2017

So thankful for a glimpse via tweets of research that can change the future of women with gynecologic cancers.

Dee
Every Day is a Blessing!

SGO Meeting Highlights via Twitter ~ Day Two, March 13, 2017

More news from the The Society of Gynecologic Oncology (@SGO_org) Annual Meeting. I am at home and have been following Tweets from the meeting using the hashtag #SGOmtg.

Here are some tweets I found of interest today-  Monday, March 13th.

Endometrial Cancer:

More evidence that molecular/genetic makeup of endometrial CA in blacks explains poorer prognostic factors #SGOMtg

— A.C. Evans, MD, PhD (@gynoncdoc) March 13, 2017

Maxwell: High MS7 levels in primary tumor consistently associated with poor outcome in endometrial cancer. #SGOMtg

— Don S Dizon (@drdonsdizon) March 13, 2017

Great study from @SArmbrusterMD: physical activity intervention associate w long term wt loss in EC pts at meet the prof #SGOMtg #endcancer

— Katie Kurnit (@katiekurnit) March 13, 2017

Burnout in Gynecologic  Oncologists

Dr. Fowler discussing strategies to address burnout. #SGOMtg #selfcare pic.twitter.com/AZ3SnRhUKW

— Shannon Armbruster (@SArmbrusterMD) March 13, 2017

Fowler Prez Addrs: Physician wellness=Better patient outcomes & Quality care. #SGOMtg We NEED you & we need you 2 take care of yourselves ❤

— Annie Ellis (@Stigetta) March 13, 2017

Patient Centered Assessment Tool - Great work done by my friend and fellow advocate Annie Ellis.

Poster 94: Priorities assessment tool (PAT) to support shared decision making, maximize appt time & increase patient satisfaction #SGOMtg pic.twitter.com/Kj7d1oa46M

— Annie Ellis (@Stigetta) March 13, 2017

IP Chemotherapy

OV21/PETROC trial. another trial that shows intraperitoneal chemotherapy for #ovariancancer patients is better. #SGOMtg #fightsmarter

— Rod Rocconi (@rodrocconi) March 13, 2017

Poster 148: no sig diff b/w bev and IP chemo in PFS or OS in pts with #BRCA positive #ovariancancer #SGOMtg

— Myriad myChoice (@MyriadMyChoice) March 13, 2017

Circulating DNA

ctDNA is the future of precision oncology for GYN patients and beyond! So many possibilities! #SGOMtg #endCancer

— Katie Kurnit (@katiekurnit) March 13, 2017

 Niraparib

Today we presented secondary endpoint data from our landmark NOVA trial at #SGOMtg. Read our press release for more: https://t.co/l9Hk9HULIa

— TESARO, Inc. (@TESAROBIO) March 13, 2017

Maintenance niraparib improved outcomes & not detrimental to QoL in heavily pretreated platinum sensitive gBRCAmut and non-gBRCAmut #SGOMtg pic.twitter.com/RGkJxDSkod

— Annie Ellis (@Stigetta) March 13, 2017

 Rucaparib

Latest updates for rucaparib for #ovariancancer in ARIEL2 trial , presented at @SGO_org #SGOMtg : https://t.co/ONXf5WtfMg pic.twitter.com/9TfNQoQ0wu

— ecancer (@ecancer) March 13, 2017

Genetic Testing

As we discuss genetic testing at #SGOMtg, important to remember the personal implications https://t.co/5KbrWG7NCw #ovarian cancer #gyncsm

— Dr. Robert Dood (@DrRobDood) March 13, 2017

 GPI -  Glucose-6-phosphate isomerase

Previs: High GPI levels in patients w ovca associated with worse prognosis. #SGOMtg

— Don S Dizon (@drdonsdizon) March 13, 2017

Previs: GPI: glucose 6-phosphate isomerase. Previs finds that inhibition associated with more cell kill/less tumor burden. #SGOMtg

— Don S Dizon (@drdonsdizon) March 13, 2017

Neoadjuvant Chemotherapy

R Arend: NACT for #ovariancancer leads to upregulation of #DNA damage repair pathway genes #sgomtg

— Myriad myChoice (@MyriadMyChoice) March 13, 2017

Arend: pt w/ #BRCA mutation had lowest DNA damage pathway score after NACT - further investigation needed #sgomtg

— Myriad myChoice (@MyriadMyChoice) March 13, 2017

Slides from a Sunday presentation on  PARP

Drs. Coleman, Herzog, @DrMatulonis, @ShannonWestin Downloadable Slides Now Available at https://t.co/FOiuvBPJzG from symposium at #SGOMtg pic.twitter.com/OChFoann3G

— BioAscend (@BioAscend) March 13, 2017

Thanks for all those tweeting from the meeting especially these folks

Follow the newest #socialmedia stars from @mdandersonnews 4 #gyncancer #SGOMtg updates @DrRobDood @katiekurnit @JDottinoMD @RTylerHillmanMD https://t.co/mVo1TZBt9D

— Shannon Westin (@ShannonWestin) March 13, 2017

Tweeting. #SGOMtg #gyncsm pic.twitter.com/dNrDqpZxut

— Robert Tyler Hillman (@RTylerHillmanMD) March 13, 2017

Looking forward to Tweets from tomorrow's meeting.

Dee Every Day is a Blessing!

SGO Meeting Highlights via Twitter ~ Day One, March 12, 2017

The Society of Gynecologic Oncology (@SGO_org) is holding it's Annual Meeting March 12th -15th, 2017. I'm unable to attend in person, but I will be following hashtag #SGOmtg to catch the latest news and developments. My plan is to compile noteworthy tweets each day of the meeting and share those in a blog post. 

Here are some tweets I found of interest today-  Sunday March 12th.

Hospital readmission metrics are not an ideal measure in ovarian cancer cases #SGOMtg #qualitycare pic.twitter.com/jFl5DFJt9T

— SGO (@SGO_org) March 12, 2017

@SwisherLiz Tumor factors BRCA and RAD51C methylation are also Predictors of response to PARP in #ovariancancer #SGOMtg pic.twitter.com/rh4zKVWanY

— Karen Lu (@karenluMD) March 12, 2017

Managing PARPi toxicities @ShannonWestin #parpi #SGOMtg

— Robert Tyler Hillman (@RTylerHillmanMD) March 12, 2017

@erinstevensmd @RTylerHillmanMD close monitoring. Early intervention to avoid dose interruptions or dose hold. #SGOMtg #gyncsm

— Shannon Westin (@ShannonWestin) March 12, 2017

TY Joanne Rash for great practical info on talking to survivors about sexual health! Imp QoL issue! #SGOMtg pic.twitter.com/iozdutjuol

— Annie Ellis (@Stigetta) March 12, 2017

#SGOMtg Rationale for therapeutic #cervicalcancer vaccine. pic.twitter.com/gJ4tLyTZmI

— Deanna Teoh, M.D. (@DeannaTeoh) March 12, 2017

Immune biology is complex but exciting. Must consider the microenvironment, genetics, microbiome to develop rational combinations. #SGOMtg

— Rebecca Previs (@BeccaPrevisMD) March 12, 2017

So thankful for the advocates, gyn oncs and researchers sharing what they learn via Twitter. 

Dee
Everyday is a Blessing!